Cystic Fibrosis and Its Management Through Established and Emerging Therapies

David R. Spielberg, John P. Clancy

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Cystic fibrosis (CF) is the most common life-shortening autosomal recessive disorder in the Caucasian population and occurs in many other ethnicities worldwide. The daily treatment burden is substantial for CF patients even when they are well, with numerous pharmacologic and physical therapies targeting lung disease requiring the greatest time commitment. CF treatments continue to advance with greater understanding of factors influencing long-term morbidity and mortality. In recent years, in-depth understanding of genetic and protein structure-function relationships has led to the introduction of targeted therapies for patients with specific CF genotypes. With these advances, CF has become a model of personalized or precision medicine. The near future will see greater access to targeted therapies for most patients carrying common mutations, which will mandate individualized bench-to-bedside methodologies for those with rare genotypes.

Original languageEnglish (US)
Pages (from-to)155-175
Number of pages21
JournalAnnual Review of Genomics and Human Genetics
StatePublished - 2016
Externally publishedYes


  • CF therapy
  • CFTR
  • CFTR modulator
  • cystic fibrosis
  • lung function
  • personalized medicine

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Cystic Fibrosis and Its Management Through Established and Emerging Therapies'. Together they form a unique fingerprint.

Cite this